Abstract
The objective of this study was to quantitate cefotaxime and its active metabolite, desacetyl cefotaxime, in the distal airways and to compare these levels to concentrations in plasma. Respiratory secretions were obtained from the subsegmental level in 17 adult patients undergoing fiber-optic bronchoscopy within 2 h after receiving four doses of cefotaxime (2 g intravenously every 6 h). In 11 patients, cefotaxime levels measured by high-pressure liquid chromatography in bronchial secretions were below detectable limits (less than 0.5 mg/liter); however, levels of desacetyl cefotaxime exceeded 1.5 mg/liter in 9 of these 11 patients (range, 1.6 to 10 mg/liter). Concentrations of desacetyl cefotaxime in lung secretions (6.9 +/- 0.85 [standard error] mg/liter) was 77% of mean levels of desacetyl cefotaxime in plasma (8.9 +/- 1.26 mg/liter). In summary, concentrations of desacetyl cefotaxime in bronchial secretions are markedly higher than those of cefotaxime.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Alexander M. R., Schoell J., Hicklin G., Kasik J. E., Coleman D. Bronchial secretion concentrations of tobramycin. Am Rev Respir Dis. 1982 Feb;125(2):208–209. doi: 10.1164/arrd.1982.125.2.208. [DOI] [PubMed] [Google Scholar]
- Bergogne-Berezin E., Morel C., Pierre J., Monrocq N., Dournovo P., Benard Y. Penetration of cefotaxime into bronchial secretions. Rev Infect Dis. 1982 Sep-Oct;4 (Suppl):S392–S395. doi: 10.1093/clinids/4.supplement_2.s392. [DOI] [PubMed] [Google Scholar]
- Braga P. C., Pozzato C., Cedrini C., Fraschini F., Scarpazza G., Scaglione F., Gagliardi V., Apicella F., Manganelli V., Paiola G. Clinical pharmacokinetics of cefotaxime and penetration in sputum, bone, and prostatic tissue. Clin Ther. 1982;5(1):69–78. [PubMed] [Google Scholar]
- Dull W. L., Alexander M. R., Kasik J. E. Bronchial secretion levels of amikacin. Antimicrob Agents Chemother. 1979 Dec;16(6):767–771. doi: 10.1128/aac.16.6.767. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fick R. B., Jr, Naegel G. P., Squier S. U., Wood R. E., Gee J. B., Reynolds H. Y. Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. J Clin Invest. 1984 Jul;74(1):236–248. doi: 10.1172/JCI111407. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jones R. N., Barry A. L., Thornsberry C. Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy. Rev Infect Dis. 1982 Sep-Oct;4 (Suppl):S366–S373. doi: 10.1093/clinids/4.supplement_2.s366. [DOI] [PubMed] [Google Scholar]
- Lode H., Kemmerich B., Gruhlke G., Dzwillo G., Koeppe P., Wagner I. Cefotaxime in bronchopulmonary infections--a clinical and pharmacological study. J Antimicrob Chemother. 1980 Sep;6 (Suppl A):193–198. doi: 10.1093/jac/6.suppl_a.193. [DOI] [PubMed] [Google Scholar]
- Reyes M. P. The aerobic gram-negative bacillary pneumonias. Med Clin North Am. 1980 May;64(3):363–383. doi: 10.1016/s0025-7125(16)31598-x. [DOI] [PubMed] [Google Scholar]
- Welch W. D., Bawdon R. E. Cefotaxime metabolism by hemolyzed blood: quantitation and inhibition of the deacetylation reaction. Diagn Microbiol Infect Dis. 1986 Feb;4(2):119–124. doi: 10.1016/0732-8893(86)90145-8. [DOI] [PubMed] [Google Scholar]
- Wise R., Wills P. J., Andrews J. M., Bedford K. A. Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins. Antimicrob Agents Chemother. 1980 Jan;17(1):84–86. doi: 10.1128/aac.17.1.84. [DOI] [PMC free article] [PubMed] [Google Scholar]